Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
FutuRx: TVI is a partner in the FutuRx biotechnology accelerator that was established in 2014 with OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation. FutuRx is located in the Weizmann Science Park in Ness Ziona, Israel.
We are honored to present Takeda with the America-Israel Chamber of Commerce Chicago's Business Leadership Award in recognition of its leadership advancing business between the US, Israel and Japan and specifically its investment in the FutuRx Incubator.
Tetsuyuki Maruyama, Ph.D.
Corporate Officer, General Manager & Head of the Pharmaceutical Research Division
Takeda Pharmaceutical Company, Ltd.
Trained as a neuroscientist, Tetsuyuki began his career in academics at the University of Minnesota in the US, then later at Cardiff University in the UK, where he was Professor of Neurobiology in the Cardiff School of Biosciences.
In 2003, he took his interest in the mechanisms of learning, memory and disorders of cognition into industry, moving to Merck Sharp and Dohme’s Neuroscience Research Centre in the UK. In 2005, Tetsuyuki took the opportunity to move to Singapore as Head of GlaxoSmithKline’s new Centre for Research in Cognitive and Neurodegenerative Disorders, where he stayed until 2010 before moving to Takeda.
Now working from Takeda’s new state of the art global research hub, the Shonan Research Center near Tokyo, he is responsible for ensuring that Takeda’s global drug discovery teams produce valuable new medicines for unmet medical needs in Takeda’s key therapeutic areas, including CNS, metabolic, cardiovascular, inflammation & immunology, GI & GU, vaccines and cancer (in partnership with Millennium, the Takeda Oncology Company).
In 2012, Tetsuyuki became a Japan National and changed his name (previously Paul Chapman).
Graeme Martin, Ph.D.
President and CEO
Takeda Ventures, Inc (TVI)
The strategic venture investment arm of Takeda Pharmaceutical Company, Ltd.
Since joining Takeda in 2003, Martin has overseen investment into 21 early and mid-stage biotechnology companies which have produced strategic relationships with Takeda R&D operations.
One company, Envoy Therapeutics, was acquired by Takeda in 2012. During more than 35 years in multinational Pharmaceutical and Biotech R&D, both in Europe and the USA, Martin has worked on three novel drug IND candidates, including zolmitriptan, an acute treatment for migraine now marketed worldwide under the brand name Zomig®.
He is the author of more than 85 peer-reviewed publications and book chapters. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.